Information Provided By: 
Fly News Breaks for August 31, 2016
RIGL
Aug 31, 2016 | 07:19 EDT
H.C. Wainwright analyst Shaunak Deepak raised his price target for Rigel Pharmaceuticals to $7 saying fostamatib "showed a clear benefit" in 18% of heavily-pretreated patients in the first of its two pivotal studies in idiopathic thrombocytopenic purpura. Following yesterday's data release, the analyst raised his probability of success as a late-stage ITP therapy to 80% from 60%. He keeps a Buy rating on Rigel.
News For RIGL From the Last 2 Days
There are no results for your query RIGL
